Abstract
MicroRNAs (miRNAs) play an important role in drug resistance, and it is reported that miR-27a-3p regulated the sensitivity of cisplatin in breast cancer, lung cancer and ovarian cancer. However, the relationship between miR-27a-3p and chemosensitivity of cisplatin in hepatocellular carcinoma (HCC) was unclear, especially the underlying mechanism was unknown. In the present study, we analyzed miR-27a-3p expression levels in 372 tumor tissues and 49 adjacent tissues in HCC samples from TCGA database, and found that the miR-27a-3p was down-regulated in HCC tissues. The level of miR-27a-3p was associated with metastasis, Child-Pugh grade and race. MiR-27a-3p was regarded as a favorable prognosis indicator for HCC patients. Then, miR-27a-3p was overexpressed in HepG2 cell, and was knocked down in PLC cell. Next, we conducted a series of in vitro assays, including MTT, apoptosis and cell cycle assays to observe the biological changes. Further, inhibitor rate and apoptosis rate were detected with pre- and post-cisplatin treatment in HCC. The results showed that overexpression of miR-27a-3p repressed the cell viability, promoted apoptosis and increased the percentage of cells in G0/G1 phase. Importantly, overexpression of miR-27a-3p si...Continue Reading
References
Nov 17, 2007·Cancer Research·Susanne U Mertens-TalcottStephen Safe
Jan 18, 2008·Cancer Research·Hua YangJin Q Cheng
Sep 16, 2008·Cancer Letters·Tao LiuXin Li
Nov 10, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroaki TakahashiMasao Hosokawa
Jul 14, 2010·Gynecologic Oncology·Zhimin LiZehua Wang
May 7, 2011·Critical Reviews in Oncology/hematology·Elisa GiovannettiGodefridus J Peters
Jul 23, 2011·Oncology·Makoto YamasakiYuichiro Doki
Aug 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keijiro SugimuraYuichiro Doki
Dec 21, 2012·International Journal of Oncology·Weiyi XuSongshan Jiang
Feb 23, 2013·Cancer Prevention Research·Wan-Sheng WangXiao-Lin Wang
Oct 2, 2013·Annual Review of Pathology·Gianpiero Di LevaCarlo M Croce
Jan 23, 2014·Gene·Jun QinWei Chen
Mar 29, 2014·European Journal of Internal Medicine·Dirk GrafDieter Häussinger
Aug 17, 2014·Molecular Cancer·Jipeng LiWanjun Yu
Dec 4, 2014·Obstetrics & Gynecology Science·Hyun Gyo LeeChi Heum Cho
Jan 21, 2015·Current Molecular Medicine·V Dimitrova, A Arcaro
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
May 23, 2015·Oncology Reports·Wenjun YinXiusheng He
Jun 6, 2015·Oncotarget·Wataru NakataNorio Nonomura
Aug 5, 2015·Molecular Medicine Reports·Jin MaXiaoyong Lei
Nov 21, 2015·Life Sciences·Lu GuoXiaodong Xie
Dec 15, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Sumei ZhouXiaohua Zhang
Jan 2, 2016·Oncology Letters·Xiao-Yun LiQ I Zhang
Mar 17, 2016·Scientific Reports·Nan ZhaoXiao Li
Jul 20, 2016·Oncology Reports·Guang ZengHuan Shen
Dec 10, 2016·Lancet·Jean-Charles Nault
Mar 16, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Wei MengGuihua Chen
Apr 11, 2017·Oncology Reports·Lihua Li, Zhaohui Luo
Aug 9, 2020·OncoTargets and Therapy·Bei ZhuXihu Qin